Teahose.
SIGN IN
NEW HERE — WHAT TEAHOSE DOES
We read the entire AI & tech firehose — so you don't have to.
PODPodcastsAll-In, No Priors, Acquired…
NEWNewslettersStratechery, Newcomer…
PAPPapersPhysical AI research
PHProduct Huntdaily launches
VCInvestor ScoutSequoia, a16z, Benchmark…
CLAUDE DISTILLS →
7 reads, 30 sec each — free, 6 AM ET.
+ a live graph of the companies, people & themes underneath.
HOME/PEOPLE/KEVIN EISELE
// PERSON

Kevin Eisele

ROLE HEAD OF BIOTECH CAPITAL MARKETSAT WILLIAM BLAIRMENTIONS 1LAST SEEN JUNE 1, 2026
// BIO

Kevin Eisele is a managing director in healthcare equity capital markets at William Blair, based in the firm's Chicago office. He specializes in biopharma capital raising and is frequently cited in major financial publications on biotech IPO trends and market dynamics. He joined William Blair's investment banking team in 2011.

Discussed in
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
mention·PitchBook News·JUNE 1, 2026

Crossover investors and generalist asset managers are rotating out of over-indexed AI/tech positions and back into biopharma as a diversification play. The IPO window is reopening with conviction — deals are not just getting done, they're getting upsized.

Source

AI-extracted from podcast / newsletter / paper summaries. May contain errors.

Kevin Eisele — 1 mention on Teahose